Moderna (NASDAQ:MRNA) Given New $27.00 Price Target at Leerink Partners

Moderna (NASDAQ:MRNA) had its target price lowered by Leerink Partners from $31.00 to $27.00 in a research report sent to investors on Thursday. The brokerage currently has an underweight rating on the stock.

Several other brokerages have also commented on MRNA. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. cut their target price on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Bank of America reissued an “underperform” rating and issued a $41.00 target price on shares of Moderna in a research report on Tuesday, December 10th. Sanford C. Bernstein began coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Four analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $75.58.

Moderna Stock Down 2.9 %

Shares of NASDAQ MRNA opened at $33.76 on Thursday. Moderna has a 1 year low of $31.94 and a 1 year high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average of $41.11 and a two-hundred day moving average of $67.32.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the company posted ($1.39) earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts anticipate that Moderna will post -9.3 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRNA. MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Blue Trust Inc. grew its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the period. Larson Financial Group LLC increased its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares in the last quarter. Rakuten Securities Inc. increased its holdings in Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after buying an additional 778 shares in the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Moderna during the 2nd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.